Sarepta Therapeutics, Inc. has grown revenue 25% a year over three years and 27% a year over five. Revenue growth, 3-year annual rate: +25% (Biotechnology median +17%). Revenue growth, 5-year rate: +27%, growth has slowed since the five-year average. Years of annual history on file: 17, FY2009 to FY2025, as filed.

SRPTSarepta Therapeutics, Inc.

Healthcare

$17.85+2.4% 1Y

$17.85

$15.0052 weeks$24.45

Is it growing?

Watch

Growth is fading: revenue shrinking (−20% year on year) and operating margin narrowing (−18.6 points).

2 to watch, 1 without data

Revenue trend−20% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +27% a year.

Margin direction−18.6 points operating

Trailing-twelve-month operating margin, -16.6% now against 2.0% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 8% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is SRPT growing?

Sarepta Therapeutics, Inc. has grown revenue 25% a year over three years and 27% a year over five.

+25%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +27%
Revenue growth, 5-year rate · +25% over three · growth has slowed since the five-year average
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed

Details›